JPWO2019099732A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019099732A5 JPWO2019099732A5 JP2020545038A JP2020545038A JPWO2019099732A5 JP WO2019099732 A5 JPWO2019099732 A5 JP WO2019099732A5 JP 2020545038 A JP2020545038 A JP 2020545038A JP 2020545038 A JP2020545038 A JP 2020545038A JP WO2019099732 A5 JPWO2019099732 A5 JP WO2019099732A5
- Authority
- JP
- Japan
- Prior art keywords
- proteins
- protein
- fragments
- biomarkers
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 375
- 108090000623 proteins and genes Proteins 0.000 claims description 375
- 239000000090 biomarker Substances 0.000 claims description 213
- 239000000203 mixture Substances 0.000 claims description 83
- 239000000523 sample Substances 0.000 claims description 36
- 208000001183 Brain Injury Diseases 0.000 claims description 24
- 210000001519 tissues Anatomy 0.000 claims description 24
- 239000012472 biological sample Substances 0.000 claims description 22
- 210000004556 Brain Anatomy 0.000 claims description 20
- 206010052639 Nerve injury Diseases 0.000 claims description 19
- 230000002503 metabolic Effects 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 18
- 230000002757 inflammatory Effects 0.000 claims description 16
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 claims description 14
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 claims description 14
- 229940077737 Brain-Derived Neurotrophic Factor Drugs 0.000 claims description 14
- 101700070897 ENO2 Proteins 0.000 claims description 14
- 102100003738 ENO2 Human genes 0.000 claims description 14
- 102000001389 Glial Fibrillary Acidic Protein Human genes 0.000 claims description 14
- 108010093505 Glial Fibrillary Acidic Protein Proteins 0.000 claims description 14
- 108010015301 Neurogranin Proteins 0.000 claims description 14
- 102000001775 Neurogranin Human genes 0.000 claims description 14
- 102100018527 SNCB Human genes 0.000 claims description 14
- 101710019469 SNCB Proteins 0.000 claims description 14
- 238000004166 bioassay Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 210000004369 Blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 102000034377 signal transducing proteins Human genes 0.000 claims description 10
- 108091006008 signal transducing proteins Proteins 0.000 claims description 10
- -1 ICAM5 Proteins 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 9
- 230000003107 synaptogenic Effects 0.000 claims description 9
- 206010070976 Craniocerebral injury Diseases 0.000 claims description 8
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000015788 innate immune response Effects 0.000 claims description 6
- 210000001130 Astrocytes Anatomy 0.000 claims description 5
- 102000014914 Carrier Proteins Human genes 0.000 claims description 5
- 108010078791 Carrier Proteins Proteins 0.000 claims description 5
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 claims description 5
- 210000000981 Epithelium Anatomy 0.000 claims description 5
- 210000001153 Interneurons Anatomy 0.000 claims description 5
- 210000004185 Liver Anatomy 0.000 claims description 5
- 102000028664 Microtubules Human genes 0.000 claims description 5
- 108091022031 Microtubules Proteins 0.000 claims description 5
- 210000000461 Neuroepithelial Cells Anatomy 0.000 claims description 5
- 210000003491 Skin Anatomy 0.000 claims description 5
- 230000022534 cell killing Effects 0.000 claims description 5
- 210000004027 cells Anatomy 0.000 claims description 5
- 230000015271 coagulation Effects 0.000 claims description 5
- 238000005345 coagulation Methods 0.000 claims description 5
- 230000009089 cytolysis Effects 0.000 claims description 5
- 230000003247 decreasing Effects 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 108091006088 gene-regulatory proteins Proteins 0.000 claims description 5
- 102000034448 gene-regulatory proteins Human genes 0.000 claims description 5
- 102000019989 lipid binding proteins Human genes 0.000 claims description 5
- 230000017074 necrotic cell death Effects 0.000 claims description 5
- 210000002569 neurons Anatomy 0.000 claims description 5
- 230000002797 proteolythic Effects 0.000 claims description 5
- 230000000946 synaptic Effects 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 5
- 102000010831 Cytoskeletal Proteins Human genes 0.000 claims description 4
- 108010037414 Cytoskeletal Proteins Proteins 0.000 claims description 4
- 230000001640 apoptogenic Effects 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 230000021164 cell adhesion Effects 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 230000000977 initiatory Effects 0.000 claims description 4
- 108091015473 lipid binding proteins Proteins 0.000 claims description 4
- 230000000626 neurodegenerative Effects 0.000 claims description 4
- 230000001272 neurogenic Effects 0.000 claims description 4
- 102000021339 protein binding proteins Human genes 0.000 claims description 4
- 108091010288 protein binding proteins Proteins 0.000 claims description 4
- 108010052285 Membrane Proteins Proteins 0.000 claims description 3
- 102000018697 Membrane Proteins Human genes 0.000 claims description 3
- 210000002381 Plasma Anatomy 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000003296 Saliva Anatomy 0.000 claims description 3
- 210000002966 Serum Anatomy 0.000 claims description 3
- 210000003802 Sputum Anatomy 0.000 claims description 3
- 210000001138 Tears Anatomy 0.000 claims description 3
- 210000002700 Urine Anatomy 0.000 claims description 3
- 230000001472 cytotoxic Effects 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 230000001225 therapeutic Effects 0.000 claims description 3
- 102000001390 EC 4.1.2.13 Human genes 0.000 claims description 2
- 108010068561 EC 4.1.2.13 Proteins 0.000 claims description 2
- 238000002318 immunoblotting Methods 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 230000003834 intracellular Effects 0.000 claims description 2
- 238000002331 protein detection Methods 0.000 claims description 2
- 238000001711 protein immunostaining Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 101700046332 ASTN2 Proteins 0.000 claims 8
- 102100016219 ASTN2 Human genes 0.000 claims 8
- 102100015941 CUL7 Human genes 0.000 claims 8
- 101700060347 CUL7 Proteins 0.000 claims 8
- 102100019017 VWF Human genes 0.000 claims 6
- 108010047303 von Willebrand Factor Proteins 0.000 claims 6
- 229960001134 von Willebrand factor Drugs 0.000 claims 6
- 101700015573 IMMU Proteins 0.000 claims 5
- 101710004685 imm Proteins 0.000 claims 5
- 208000007333 Brain Concussion Diseases 0.000 claims 2
- 210000003169 Central Nervous System Anatomy 0.000 claims 2
- 230000001413 cellular Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 210000000056 organs Anatomy 0.000 claims 2
- 230000001991 pathophysiological Effects 0.000 claims 2
- 230000003248 secreting Effects 0.000 claims 2
- 206010022114 Injury Diseases 0.000 claims 1
- 101710033910 MT-I Proteins 0.000 claims 1
- 230000036740 Metabolism Effects 0.000 claims 1
- 108090000157 Metallothionein Proteins 0.000 claims 1
- 102000003792 Metallothionein Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000035786 metabolism Effects 0.000 claims 1
- 230000001537 neural Effects 0.000 claims 1
- 238000002731 protein assay Methods 0.000 claims 1
- 108010083077 roundabout protein Proteins 0.000 claims 1
- 102100006003 MT3 Human genes 0.000 description 10
- 108010075381 growth inhibitory factor Proteins 0.000 description 10
- 102000004965 antibodies Human genes 0.000 description 6
- 108090001123 antibodies Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000038129 antigens Human genes 0.000 description 6
- 108091007172 antigens Proteins 0.000 description 6
- 102000003852 Autoantibodies Human genes 0.000 description 5
- 108090000206 Autoantibodies Proteins 0.000 description 5
- 201000008839 post-traumatic stress disease Diseases 0.000 description 5
- 210000002216 Heart Anatomy 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 206010002855 Anxiety Diseases 0.000 description 3
- 206010057666 Anxiety disease Diseases 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 206010015037 Epilepsy Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 206010017577 Gait disturbance Diseases 0.000 description 3
- 206010019233 Headache Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010040984 Sleep disease Diseases 0.000 description 3
- 206010040998 Sleep disturbance Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000000926 neurological Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 210000004688 Microtubules Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001149 cognitive Effects 0.000 description 2
- 239000003145 cytotoxic factor Substances 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003565 oculomotor Effects 0.000 description 2
- 108091005618 post-translationally modified proteins Proteins 0.000 description 2
- 102000035360 post-translationally modified proteins Human genes 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 102100013100 DNM2 Human genes 0.000 description 1
- 101710031877 DNM2 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000002589 Oculomotor Nerve Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 101700086516 atp-9 Proteins 0.000 description 1
- 101700015611 atpH Proteins 0.000 description 1
- 101710043468 atpP Proteins 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 108091005991 citrullinated proteins Proteins 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 101710043458 oli Proteins 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024001282A JP2024038290A (ja) | 2017-11-16 | 2024-01-09 | 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587272P | 2017-11-16 | 2017-11-16 | |
| US62/587,272 | 2017-11-16 | ||
| PCT/US2018/061372 WO2019099732A1 (en) | 2017-11-16 | 2018-11-15 | Protein biomarker indicators of neurological injury and/or disease and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001282A Division JP2024038290A (ja) | 2017-11-16 | 2024-01-09 | 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503610A JP2021503610A (ja) | 2021-02-12 |
| JP2021503610A5 JP2021503610A5 (ru) | 2021-12-23 |
| JPWO2019099732A5 true JPWO2019099732A5 (ru) | 2022-09-28 |
Family
ID=66538796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545038A Pending JP2021503610A (ja) | 2017-11-16 | 2018-11-15 | 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法 |
| JP2024001282A Pending JP2024038290A (ja) | 2017-11-16 | 2024-01-09 | 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024001282A Pending JP2024038290A (ja) | 2017-11-16 | 2024-01-09 | 神経損傷および／または疾患のタンパク質バイオマーカー指標及びその使用の方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11988676B2 (ru) |
| EP (1) | EP3710836A4 (ru) |
| JP (2) | JP2021503610A (ru) |
| WO (1) | WO2019099732A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3779448A1 (en) * | 2019-08-12 | 2021-02-17 | Baden-Württemberg Stiftung gGmbH | Novel diagnostic marker for creutzfeldt-jakob disease and alzheimer's disease |
| US20220326258A1 (en) * | 2019-09-13 | 2022-10-13 | Northwestern University | Biomarkers for amyotrophic lateral sclerosis (als) and motor neuron diseases |
| EP4111197A1 (en) * | 2020-02-25 | 2023-01-04 | Markus Otto | Diagnosing a disease associated with synaptic degeneration using an elisa for determining a beta-synuclein concentration in csf |
| EP4296671A1 (en) * | 2021-02-17 | 2023-12-27 | Fujita Academy | Marker for lymphocytic adenohypophysitis and related diseases, and use of said marker |
| WO2023092157A1 (en) * | 2021-11-22 | 2023-05-25 | Brainbox Solutions, Inc. | Biomarker testing for chronic persistent injury following brain trauma |
| WO2024050133A1 (en) * | 2022-09-01 | 2024-03-07 | GATC Health Corp | Digital twin for diagnostic and therapeutic use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60233949D1 (de) * | 2001-08-20 | 2009-11-19 | Biosite Inc | Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon |
| CA2804763C (en) * | 2010-07-14 | 2023-01-03 | The Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
| AU2011334548B2 (en) * | 2010-11-26 | 2016-06-09 | Immunexpress Pty Ltd | Diagnostic and/or screening agents and uses therefor |
| EP2607900A1 (de) * | 2011-12-22 | 2013-06-26 | Protagen AG | Markersequenzen für Brustkrebs und deren Verwendung |
| EP3274709B1 (en) * | 2015-03-27 | 2021-07-07 | The Translational Genomics Research Institute | Methods of prognosing mild traumatic brain injuries |
| US10557859B2 (en) * | 2015-05-05 | 2020-02-11 | The Regents Of The University Of California | Astrocyte traumatome and neurotrauma biomarkers |
| CN107923917A (zh) | 2015-06-18 | 2018-04-17 | 西达-赛奈医疗中心 | 瓜氨酸化在诊断疾病中的作用 |
| US20170145506A1 (en) * | 2015-11-24 | 2017-05-25 | University Of Rochester | Signature of Longitudinal Gene Expression Changes to Diagnose Brain Injury |
-
2018
- 2018-11-15 US US16/763,794 patent/US11988676B2/en active Active
- 2018-11-15 EP EP18879163.6A patent/EP3710836A4/en active Pending
- 2018-11-15 JP JP2020545038A patent/JP2021503610A/ja active Pending
- 2018-11-15 WO PCT/US2018/061372 patent/WO2019099732A1/en unknown
-
2024
- 2024-01-09 JP JP2024001282A patent/JP2024038290A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mecocci et al. | Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia | |
| TW201606307A (zh) | 阿茲海默症及其他神經退化性疾病之生物標記及診斷方法 | |
| EP2796878A1 (en) | New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof | |
| ES2353722T3 (es) | Procedimiento de diagnosis in vitro por examen del líquido cefalorraquídeo para el diagnóstico de enfermedades de demencia y enfermedades neuroinflamatorias. | |
| Ichinose et al. | Novel anti-suprabasin antibodies may contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus | |
| US20150072360A1 (en) | Biomarkers of pulmonary hypertension | |
| Tawalbeh et al. | Serum protein biomarkers for juvenile dermatomyositis: a pilot study | |
| Stampanoni Bassi et al. | Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis | |
| Rodrigues-Amorim et al. | Proteomics in schizophrenia: a gateway to discover potential biomarkers of psychoneuroimmune pathways | |
| US9977036B2 (en) | Diagnostic markers for multiple sclerosis | |
| KR100689995B1 (ko) | 알돌라제를 포함하는 망막혈관 질환 진단용 조성물 및 그진단방법 | |
| Al-Temaimi et al. | Remyelination modulators in multiple sclerosis patients | |
| Tian et al. | Pigment epithelium-derived factor alleviates depressive-like behaviors in mice by modulating adult hippocampal synaptic growth and Wnt pathway | |
| JP5934183B2 (ja) | ミオパチーを特性化するための組成物及び方法 | |
| Jasiak-Zatońska et al. | Relationship between blood-brain permeability and antibodies against aquaporins in neuromyelitis optica spectrum disorders and multiple sclerosis patients | |
| Hjæresen et al. | MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis | |
| ES2400255T3 (es) | Procedimiento in vitro para la diagnosis y la diagnosis precoz de enfermedades neurodegenerativas | |
| JPWO2019099732A5 (ru) | ||
| Bagheri et al. | GFAP and neuron specific enolase (NSE) in the serum of suicide attempters | |
| Mashayekhi et al. | Quantitative analysis of cerebrospinal fluid brain derived neurotrophic factor in the patients with multiple sclerosis | |
| Cappelletti et al. | Toll‐like receptors and IL‐7 as potential biomarkers for immune‐mediated necrotizing myopathies | |
| Golubev et al. | Molecular markers of ischemic stroke | |
| CN114137214B (zh) | 用于预测应激后精神心理症状发生的免疫检测试剂盒及应用 | |
| KR102681006B1 (ko) | 뇌의 레닌-안지오텐신 시스템 인자를 이용한 알츠하이머병의 진단 방법 | |
| US20140322211A1 (en) | Tenascin-c and use thereof in rheumatoid arthritis |